Logo image of ANNX

ANNEXON INC (ANNX) Stock Fundamental Analysis

NASDAQ:ANNX - Nasdaq - US03589W1027 - Common Stock - Currency: USD

2.61  +0.03 (+1.16%)

After market: 2.68 +0.07 (+2.68%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ANNX. ANNX was compared to 558 industry peers in the Biotechnology industry. While ANNX has a great health rating, there are worries on its profitability. ANNX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ANNX had negative earnings in the past year.
In the past year ANNX has reported a negative cash flow from operations.
In the past 5 years ANNX always reported negative net income.
ANNX had a negative operating cash flow in each of the past 5 years.
ANNX Yearly Net Income VS EBIT VS OCF VS FCFANNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

ANNX has a Return On Assets (-55.24%) which is comparable to the rest of the industry.
ANNX has a Return On Equity of -68.66%. This is comparable to the rest of the industry: ANNX outperforms 56.27% of its industry peers.
Industry RankSector Rank
ROA -55.24%
ROE -68.66%
ROIC N/A
ROA(3y)-44.79%
ROA(5y)-39.91%
ROE(3y)-54.04%
ROE(5y)-47.75%
ROIC(3y)N/A
ROIC(5y)N/A
ANNX Yearly ROA, ROE, ROICANNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ANNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANNX Yearly Profit, Operating, Gross MarginsANNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, ANNX has more shares outstanding
ANNX has less shares outstanding than it did 5 years ago.
There is no outstanding debt for ANNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ANNX Yearly Shares OutstandingANNX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
ANNX Yearly Total Debt VS Total AssetsANNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -1.70, we must say that ANNX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ANNX (-1.70) is comparable to the rest of the industry.
ANNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.7
ROIC/WACCN/A
WACCN/A
ANNX Yearly LT Debt VS Equity VS FCFANNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

ANNX has a Current Ratio of 7.99. This indicates that ANNX is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 7.99, ANNX is doing good in the industry, outperforming 70.25% of the companies in the same industry.
A Quick Ratio of 7.99 indicates that ANNX has no problem at all paying its short term obligations.
ANNX has a better Quick ratio (7.99) than 70.43% of its industry peers.
Industry RankSector Rank
Current Ratio 7.99
Quick Ratio 7.99
ANNX Yearly Current Assets VS Current LiabilitesANNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

ANNX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.73%, which is quite good.
EPS 1Y (TTM)19.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.19%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 31.12% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-45.29%
EPS Next 2Y-19.4%
EPS Next 3Y4.92%
EPS Next 5Y31.12%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANNX Yearly Revenue VS EstimatesANNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
ANNX Yearly EPS VS EstimatesANNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ANNX. In the last year negative earnings were reported.
Also next year ANNX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANNX Price Earnings VS Forward Price EarningsANNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANNX Per share dataANNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.4%
EPS Next 3Y4.92%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ANNX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANNEXON INC

NASDAQ:ANNX (7/14/2025, 8:22:57 PM)

After market: 2.68 +0.07 (+2.68%)

2.61

+0.03 (+1.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/bmo
Earnings (Next)08-11 2025-08-11
Inst Owners96.19%
Inst Owner Change0%
Ins Owners0.57%
Ins Owner Change-5.15%
Market Cap286.34M
Analysts84.29
Price Target11.83 (353.26%)
Short Float %9.89%
Short Ratio6.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.28%
Min EPS beat(2)-22.39%
Max EPS beat(2)-20.16%
EPS beat(4)2
Avg EPS beat(4)-8.96%
Min EPS beat(4)-22.39%
Max EPS beat(4)5.28%
EPS beat(8)6
Avg EPS beat(8)6.77%
EPS beat(12)9
Avg EPS beat(12)9.04%
EPS beat(16)10
Avg EPS beat(16)5.9%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-23.93%
EPS NQ rev (1m)-4.49%
EPS NQ rev (3m)-19.81%
EPS NY rev (1m)-8.29%
EPS NY rev (3m)-15.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.17
P/tB 1.17
EV/EBITDA N/A
EPS(TTM)-1.18
EYN/A
EPS(NY)-1.45
Fwd EYN/A
FCF(TTM)-1.28
FCFYN/A
OCF(TTM)-1.27
OCFYN/A
SpS0
BVpS2.22
TBVpS2.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -55.24%
ROE -68.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.79%
ROA(5y)-39.91%
ROE(3y)-54.04%
ROE(5y)-47.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.14%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.99
Quick Ratio 7.99
Altman-Z -1.7
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)106.39%
Cap/Depr(5y)92.98%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.19%
EPS Next Y-45.29%
EPS Next 2Y-19.4%
EPS Next 3Y4.92%
EPS Next 5Y31.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-39.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-65.93%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-16.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.46%
OCF growth 3YN/A
OCF growth 5YN/A